Citations

Clear

585 citation(s) found for "Tran, T".

Ultrasound-Guided Gluteal Fascial Plane Block for the Treatment of Chronic Refractory Greater Trochanteric Pain Syndrome — Technique Description and Anatomical Correlation Study
Ferreira‐Dos‐Santos, Guilherme , Hurdle, Mark Friedrich B., Tran, John , Eldrige, Jason S. , Clendenen, Steven R. , Agur, Anne Maria Reet

Mayo Clinic

Pain Medicine | April 26, 2022 | Volume: 23 | Issue: 11 | Pages: 1875-1881

10.1093/pm/pnac071 | PMID 35511153 Get It

Abstract Introduction Greater trochanteric pain syndrome may often mimic pain generated from other sources. However, it is most commonly caused by gluteus medius and gluteus minimus tendinopathy or tear. The purpose of this technical report was to: 1) describe the ultrasound-guided fascial plane block technique targeting the superior gluteal nerve in the plane between gluteus medius/gluteus minimus to treat moderate-to-severe, chronic, refractory greater trochanteric pain syndrome; 2) anatomically correlate the procedure with cadaveric dissections demonstrating the structures being imaged and the tissues along the needle trajectory; 3) demonstrate the feasibility of the technique with serial dissection of one cadaveric specimen following injection with color dye. Technique description The ultrasound-guided fascial plane block targeting the superior gluteal nerve to treat moderate-to-severe, chronic, refractory greater trochanteric pain syndrome has been outlined with supporting ultrasound scans and anatomical dissections. The cadaveric dissections are correlated to the ultrasound scans of a healthy volunteer and provide visualization of the tissues in the needle trajectory. The feasibility study in a cadaveric specimen showed adequate stain of the superior gluteal nerve without spread to the piriformis muscle belly, the sciatic nerve, or the inferior gluteal nerve. Conclusions This ultrasound-guided fascial plane block is a feasible option for blocking the superior gluteal nerve without inadvertent involvement of the sciatic and inferior gluteal nerves. Further randomized controlled clinical trials are necessary to assess the clinical efficacy of the gluteus medius/gluteus minimus fascial plane block to treat moderate-to-severe, chronic, refractory greater trochanteric pain syndrome.
“It’s Like You Stuck a Pin in It:” African American/Black Patients Describe Cutaneous Toxicity From Epidermal Growth Factor Receptor Inhibitors
Martin, Nichole , Asiedu, Gladys B. , Jatoi, Aminah , Nguyen, Phuong L., Martin, Nichole A, Asiedu, Gladys, Jatoi, Aminah , Tran, Nguyen H. , Nguyen, Phuong , Le‐Rademacher, Jennifer

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | April 20, 2022 | Volume: 40 | Issue: 3 | Pages: 337-340

10.1177/10499091221092698 | PMID 35442101 Get It

Background: Epidermal growth factor receptor (EGFR) inhibitors cause cutaneous toxicity in over 90% of patients. Conceivably, healthcare providers could overlook such toxicity in African American/Black patients because of a darker complexion. This qualitative study sought to learn about such cutaneous signs and symptoms and, if present, to report them in patients’ own words. Methods: Any patient who self-identified as African American/Black and who had been prescribed an EGFR inhibitor was eligible. The current report focuses on patients’ responses to the following question, “What have you noticed since starting your cancer treatment (the EGFR inhibitor), any particular symptoms or reactions, positive or negative?” All interview data were audio-recorded, transcribed, and then independently coded and analyzed by two investigators. Results: Fifteen patients are the focus of this report, and all described cutaneous toxicity. Patients appeared troubled by the cosmetic aspect of these drug-induced skin changes, including their acneiform appearance, describing “little pimples with little, little pus in it.” Notable were comments on hyperpigmentation, “I’m a black person but…. became darker.” Furthermore, patients experienced physical symptoms: “it itches;” “it’s like you stuck a pin in it;” “stinging;” and “burning;”. Conclusion: Although cutaneous toxicity from EGFR inhibitors might be more difficult to visualize among darkly complected patients, the graphic descriptions offered in this qualitative study underscore the need for clinicians to heighten their awareness of such toxicity in African American/Black patients.
Lymphatic Mapping Using US Microbubbles before Lymphaticovenous Anastomosis Surgery for Lymphedema
Jang, Samuel , Lee, Christine U. , Hesley, Gina K. , Knudsen, John M. , Brinkman, Nathan , Tran, Nho V. , Hesley, Gina , Brinkman, Nathan J

Mayo Clinic

Radiology | April 5, 2022 | Volume: 304 | Issue: 1 | Pages: 218-224

10.1148/radiol.212351 | PMID 35380494 Get It

CLO22-088: Phase II Trial of Trifluridine/Tipiracil in Combination With Irinotecan in Advanced Biliary Tract Cancers (BTCs)
Tella, Sri Harsha , Wessling, Jaclynn, Nathan, Foster, Qian, Shi, Nguyen, Tran, McWillimas, Robert, Steven, Alberts, Liu, Minetta C. , Hartgers, Mindy L., Washburn, Leslie, Briant, Fruth, Fernández-Zapico, Martín E. , Hogenson, Tara L. , Pitot, Henry C., Qian, Shi, Borad, Mitesh J. , Wee, Wen , Jin, Zhaohui , Mahipal, Amit

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 31, 2022 | Volume: 20 | Issue: 3.5 | Pages: CLO22-088

10.6004/jnccn.2021.7328 Get It

The Arched Rainbow Brow in Thyroid Eye Disease
Tran, Ann Q. , Yang, Cameron, Tooley, Andrea A. , Mahan, Marielle, Jamerson, Emery C., Kazim, Michael, Glass, Lora R. Dagi

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | March 30, 2022 | Volume: 38 | Issue: 5 | Pages: 469-474

10.1097/iop.0000000000002168 | PMID 35353778 Get It

Purpose: To morphologically describe and mathematically quantify a novel clinical feature of thyroid eye disease (TED). Methods: A retrospective study was conducted of TED patients and age-sex-matched normal controls. The arched Rainbow Brow appearance in TED patients was determined by unanimous agreement of 3 oculoplastic surgeons. Eyebrow curvature was assessed by plotting 15 points along the eyebrow in ImageJ. The fourth-degree polynomial (y = ax4 + bx3 + cx2 + dx + e) was fitted to each eyebrow. Results: Two hundred seventy-one eyes were analyzed (200 TED and 71 age-sex-matched normal controls). A Rainbow Brow was identified in 42% of TED patients. A unilateral Rainbow Brow was seen in 15% of patients. The fourth-degree polynomial coefficients yielded significant differences between Rainbow Brow patients and age-sex-matched normal controls for the coefficients a, b, c, and d. Similar analysis of TED patients with and without a Rainbow Brow showed differences in coefficients a and b. Age >50 years (p = 0.009) and the presence of brow fat expansion (p < 0.001) were associated with the presence of a Rainbow Brow. Proptosis >24 mm showed a trend toward association with the presence of a Rainbow Brow (p = 0.057). When considering the contribution of these features in a multivariable analysis, only brow fat expansion was a significant contributing factor (p = 0.009). Conclusions: The Rainbow Brow is a distinct entity in TED and is likely consequent to brow fat pad expansion. Patients with a Rainbow Brow have different eyebrow curvature as compared to both normal age-sex-matched controls and TED patients without a Rainbow Brow.
Mapping multiregional image-localized biopsies to MRI habitats reveal biologically significant glioma tissue states and patterns of cellular subpopulations
Curtin, Lee , Bond, Kamila M. , Jackson, Pamela , Hawkins‐Daarud, Andrea , Velez, Sebastian, Shakir, Neha, Urcuyo, Javier , León, Gustavo De , Singleton, Kyle , Langworthy, Jazlynn , Clark-Swanson, Kamala R., Lassiter-Morris, Yvette, Paulson, Lisa, Sereduk, Christopher, Krishna, Chandan , Zimmerman, Richard S. , Patra, Devi Prasad, Smith, Kris A. , Donev, Kliment , Tran, Nhan L. , Hu, Leland , Plaisier, Christopher, Mrugała, Maciej M. , Canoll, Peter , Swanson, Kristin R. , Swanson, Kristin R , Tran, Nhan L , Velez, Sebastian, Shakir, Neha, Leon, Gustavo De, Clark-Swanson, Kamala R., Lassiter-Morris, Yvette, Paulson, Lisa, Sereduk, Chris , Bendok, Bernard R. , Nakaji, Peter , Baxter, Leslie C. , Plaisier, Christopher, Anderson, Alexander R A , Grinband, Jack , Al‐Dalahmah, Osama , Rubin, Joshua B

Mayo Clinic

No container title available | March 26, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2022.03.23.485500 Get It

Abstract Background Magnetic Resonance Imaging (MRI) is the mainstay for neurosurgical oncology but not for informing us about glioma biology. An obstacle to developing MR-based glioma biomarkers is the absence of rigorous correlation between MRI features and glioma biology as assessed in multi-regional biopsies, within and across patients. Methods We directly addressed this obstacle by collating a unique cohort of 202 MRI-localized biopsies from 58 patients. We define a low-dimensional transcriptional pseudotime continuum along which heterogeneous high-grade glioma (HGG) samples organize both within and across patients. Results We observe three polarized transcriptional tissue states: infiltrated brain, immune/inflammatory, and proliferative associated with patterns of cohabitation of cellular subpopulations. The states and deconvolved populations show correlation with enhancement status on T1Gd MRI. Moreover, discrete MRI habitats, regions sharing common imaging features, defined as combinations of high or low signal intensity across multiparametric MRI revealed 14 MRI habitats. We order the MRI habitats according to the average pseudotime on the transcriptional continuum. We find that MRI habitats with low pseudotime (associated with early tumor development and diffusely invaded brain tissue) localized at the periphery of the tumor whilst high pseudotime either proliferative or immune/inflammatory states were towards the core of the lesion. We find that composition of MRI habitats are impacted by MGMT status and patient sex. Conclusion This suggests that ongoing aggregation of MRI-localized biopsies may augment our projection of biology onto MRI habitats to support tracking of the evolution of cellular ecologies within and across each patient’s tumor over time. Key Points Trajectory inference of HGG samples reveals a continuum connecting three polarized tissue states reflecting transitions in cellular population ecologies and gene set enrichment Combining multiparametric MRI features into regional MRI habitats reveal clinically-distinct patterns of cell co-habitation and tissue state MGMT methylation status shifts the cellular patterns of cohabitation within MRI habitats Importance of the Study Regional heterogeneity is a defining characteristic of high-grade glioma (HGG). Mapping the transcriptomic biology of multiregionally sampled MRI-localized biopsies from high-grade gliomas onto a low-dimensional space reveals a continuum between three primary tissue states: infiltrated brain, immune/inflammatory, and proliferative. Each state is associated with distinct cell cohabitation ecologies. Transitions between the tissue states coordinate with changes in tumor composition, revealing potential direct connections between tumor biology shifts and their manifestation on clinical imaging.
Patient-specific deep learning model to enhance 4D-CBCT image for radiomics analysis
Zhang, Zeyu , Huang, Mi , Jiang, Zhuoran , Chang, Yushi , Lü, Ke , Yin, F , Tran, Phuoc , Wu, Dapeng , Beltran, Chris , Ren, Lei , Beltran, Chris J

Mayo Clinic

Physics in Medicine & Biology | March 21, 2022 | Volume: 67 | Issue: 8 | Pages: 085003

10.1088/1361-6560/ac5f6e | PMID 35313293 Get It

Abstract Objective. 4D-CBCT provides phase-resolved images valuable for radiomics analysis for outcome prediction throughout treatment courses. However, 4D-CBCT suffers from streak artifacts caused by under-sampling, which severely degrades the accuracy of radiomic features. Previously we developed group-patient-trained deep learning methods to enhance the 4D-CBCT quality for radiomics analysis, which was not optimized for individual patients. In this study, a patient-specific model was developed to further improve the accuracy of 4D-CBCT based radiomics analysis for individual patients. Approach. This patient-specific model was trained with intra-patient data. Specifically, patient planning 4D-CT was augmented through image translation, rotation, and deformation to generate 305 CT volumes from 10 volumes to simulate possible patient positions during the onboard image acquisition. 72 projections were simulated from 4D-CT for each phase and were used to reconstruct 4D-CBCT using FDK back-projection algorithm. The patient-specific model was trained using these 305 paired sets of patient-specific 4D-CT and 4D-CBCT data to enhance the 4D-CBCT image to match with 4D-CT images as ground truth. For model testing, 4D-CBCT were simulated from a separate set of 4D-CT scan images acquired from the same patient and were then enhanced by this patient-specific model. Radiomics features were then extracted from the testing 4D-CT, 4D-CBCT, and enhanced 4D-CBCT image sets for comparison. The patient-specific model was tested using 4 lung-SBRT patients’ data and compared with the performance of the group-based model. The impact of model dimensionality, region of interest (ROI) selection, and loss function on the model accuracy was also investigated. Main results. Compared with a group-based model, the patient-specific training model further improved the accuracy of radiomic features, especially for features with large errors in the group-based model. For example, the 3D whole-body and ROI loss-based patient-specific model reduces the errors of the first-order median feature by 83.67%, the wavelet LLL feature maximum by 91.98%, and the wavelet HLL skewness feature by 15.0% on average for the four patients tested. In addition, the patient-specific models with different dimensionality (2D versus 3D) or loss functions (L1 versus L1 + VGG + GAN) achieved comparable results for improving the radiomics accuracy. Using whole-body or whole-body+ROI L1 loss for the model achieved better results than using the ROI L1 loss alone as the loss function. Significance. This study demonstrated that the patient-specific model is more effective than the group-based model on improving the accuracy of the 4D-CBCT radiomic features analysis, which could potentially improve the precision for outcome prediction in radiotherapy.
Reply to A. Rizzo et al
Gile, Jennifer , Jatoi, Amina, Wee, Wen , Borad, Mitesh J. , Tran, Nguyen H. , Jatoi, Aminah , Ma, Wen Wee , Borad, Mitesh J , Gile, Jennifer Jane , Tran, Nguyen

Mayo Clinic

JCO Precision Oncology | March 16, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/po.22.00061 | PMID 35294225 Get It

A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
Uchio, Edward , Lamm, Donald L. , Tyson, Mark D. , Tran, Ben, Anderson, Paul , Grandi, Paola , Shore, Neal D. , Kamat, Ashish M. , Grandi, Paola, Burke, James M.

Mayo Clinic

Journal of Clinical Oncology | February 16, 2022 | Volume: 40 | Issue: 6_suppl | Pages: TPS598-TPS598

10.1200/jco.2022.40.6_suppl.tps598 Get It

TPS598 Background: CG0070 is a serotype 5 adenovirus engineered to express GM-CSF and replicate in cells with mutated or deficient RB, with response rates (RR) of approximately 45% observed in patients with recurrent NMIBC after BCG (J Urol. 2012;188:2391–7; Urol Oncol. 2018;36(10):440–7). This single arm phase 3 study (NCT04452591) was launched to confirm the clinical activity of CG0070 in patients with BCG Unresponsive NMIBC. Methods: 110 patients with BCG-unresponsive CIS with or without concurrent Ta or T1 disease will be treated with intravesical (IVe) CG0070 at a dose of 1x1012 vp. CG0070 will be administered as follows: induction weekly x 6 followed by weekly x 3 maintenance instillations at months 3, 6, 9, 12, and 18. Patients with persistent CIS or HG Ta at 3 months (m) may receive re-induction with weekly x 6 CG0070. Assessment of response will include q 3 m cystoscopy with biopsy of areas suspicious for disease, urine cytology, CTU/MRU, and mandatory bladder mapping at 12 m. Detection of high grade disease within the bladder will be enumerated as recurrence or non-response. The primary endpoint of the study is CR at any time on study as assessed by biopsy (directed to cystoscopic abnormalities and mandatory mapping at 12 m), urine cytology, and radiography, as above. Secondary endpoints include CR at 12 m, duration of response, progression free survival, cystectomy free survival and safety. Correlative assessments include changes in the tumor immune microenvironment, systemic immune induction as reflected in the peripheral blood and urine, as well as viral replication and transgene expression. Baseline expression of coxsackie adenovirus receptor, E2F transcription factor as well as anti-adenovirus antibody titer will be correlated with tumor response. Study enrollment globally is ongoing including in North America, Taiwan, Japan, and South Korea. Refs. Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, Aimi J, Lerner S, Yeung AW, Kazarian T, Maslyar DJ, McKiernan JM. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. Clinical trial information: NCT04452591.
Adjunctive Middle Turbinectomy for Endoscopic Medial Orbital Wall – Thyroid Eye Disease Decompression
Tooley, Andrea A. , Kim, Matthew , Tran, Ann Q. , Kazim, Michael, Gudis, David A.

Mayo Clinic

International Archives of Otorhinolaryngology | February 8, 2022 | Volume: 26 | Issue: 04 | Pages: e579-e584

10.1055/s-0041-1740156 | PMID 36405464 Get It

Abstract Introduction Middle turbinate resection (MTR) is commonly performed during endonasal endoscopic sinus and skull base surgery. Objective The purpose of this study was to characterize the additional orbital soft-tissue volume expansion during endoscopic medial orbital wall decompression with adjunctive MTR. Methods A retrospective review of patients who underwent endoscopic medial wall decompression with MTR was performed. The imaging software AW (GE Healthcare, Chicago, IL, USA) was used to overlay pre and postoperative orbital computed tomography (CT) images to visualize the preoperative position of the middle turbinate and the postoperative orbital soft tissue in the ethmoid bed. The imaging software Vitrea (Vital Images Inc., Minnetonka, MN, USA) was used to manually segment postoperative scans to determine the volume of orbital tissue which had filled the space previously occupied by the middle turbinate or medial to it. Results Nine orbits from 5 patients were included in this study; all patients were female with a history of hyperthyroidism. The average age was 55.6 years (range 32–74). Of the 9 orbits, 7 (78%) had orbital soft tissue within the space of the resected middle turbinate postoperatively. The average volume of orbital tissue within or medial to this space was 0.83 +/− 0.67 cc. No patients had any postoperative complications. Conclusions In this patient cohort, adjunctive middle turbinate resection for endoscopic medial orbital wall decompression added ∼ 0.83 cc of volume for orbital soft tissue after medial wall decompression. Middle turbinate resection is a useful adjunct to the orbital surgeon's armamentarium to augment the results of a medial orbital decompression for select patients.